SS-31 / Elamipretide: The Mitochondrial Peptide That Protects Cardiolipin

Elamipretide is one of the most advanced mitochondrial-targeted peptides in clinical development, with recent FDA approval for Barth syndrome.

In this post, we will discuss how SS-31 works, what cardiolipin is, why it matters for mitochondrial function, and what the clinical evidence shows for heart failure, aging, and muscle.

---

What Is SS-31 / Elamipretide

Elamipretide (SS-31) is a synthetic, aromatic-cationic tetrapeptide that targets mitochondria. R

Its structure allows it to penetrate cell membranes and accumulate in the inner mitochondrial membrane. R

It is attracted to cardiolipin, a phospholipid essential for mitochondrial structure and function. R

In September 2025, elamipretide received FDA accelerated approval under the brand name Forzinity for Barth syndrome. R

Cardiolipin And Mitochondria

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane. R

It is essential for cristae structure and the assembly of electron transport chain supercomplexes. R

When cardiolipin is oxidized or depleted, mitochondrial function collapses. R

Elamipretide binds to cardiolipin, preventing its peroxidation and stabilizing the inner mitochondrial membrane. R

This prevents the formation of the mitochondrial permeability transition pore and reduces the release of pro-apoptotic factors. R

Heart Failure And Barth Syndrome

Barth Syndrome

Barth syndrome is a rare genetic disorder caused by mutations in the TAZ gene, which impairs cardiolipin remodeling. R

Elamipretide has been studied extensively in this population and showed improvements in mitochondrial bioenergetics and ventricular structure. R

The TAZPOWER trial supported its efficacy in Barth syndrome. R

Heart Failure

Preclinical studies showed that elamipretide improves left ventricular ejection fraction and exercise tolerance. R

Clinical trials in broader heart failure populations have shown mixed results, with some benefits in specific subgroups. R

Skeletal Muscle And Aging

Aging is associated with progressive mitochondrial decline and sarcopenia. R

Research indicates that elamipretide can reverse aspects of muscle weakness and aging in murine models by restoring mitochondrial function. R

Human trials in age-related muscle decline are ongoing. R

Skin And Ophthalmology

Elamipretide has been studied for dry age-related macular degeneration and other ophthalmic conditions. R

Topical skin applications have limited peer-reviewed evidence, and most skin-related research involves systemic administration. R

Dosing And Administration

Most clinical trials use subcutaneous injections of elamipretide. R

Dosing is determined by clinical trial protocols and medical supervision. R

Elamipretide is not available over the counter and is not a commercial skincare product. R

Mechanisms Of Action

Simple:

Elamipretide targets mitochondria and binds to cardiolipin. It stabilizes the inner mitochondrial membrane. It improves electron transport chain efficiency and ATP production.

Advanced:

Cardiolipin binding. Elamipretide's aromatic-cationic structure allows it to bind cardiolipin through electrostatic interactions, stabilizing cristae architecture. R Prevention of cardiolipin peroxidation. By protecting cardiolipin from oxidative damage, elamipretide preserves electron transport chain supercomplex assembly. R mPTP inhibition. Elamipretide reduces mitochondrial permeability transition pore opening, preventing cell death signaling. R Reduced mitochondrial ROS. Improved electron transport efficiency decreases leakage of reactive oxygen species from Complex I and III. R

Genetics

TAZ

TAZ encodes tafazzin, an enzyme required for cardiolipin remodeling. R

Mutations cause Barth syndrome. R

COQ2 / PDSS1

These genes encode enzymes involved in CoQ10 biosynthesis. R

CoQ10 deficiency can present with similar mitochondrial dysfunction and may overlap with cardiolipin-related disease. R

SOD2

SOD2 encodes mitochondrial superoxide dismutase, which works upstream of cardiolipin oxidation. R

Variants may influence oxidative stress and mitochondrial vulnerability. R

More Research

Reperfusion injury. Elamipretide has shown protective effects in ischemia-reperfusion injury models. R Neurodegeneration. Mitochondrial dysfunction is central to many neurodegenerative diseases, and elamipretide is being explored as a potential therapy. R Aging. Elamipretide is being investigated for age-related mitochondrial decline, though human longevity data are not available. R

• Testing. For biomarker testing I use the Mitochondrial Panel and Comprehensive Metabolic Panel to assess mitochondrial and metabolic function.